Humira retained the top spot on the list of the top 20 selling drugs in 2020. The AbbVie Inc.(NYSE:ABBV) mega-blockbuster generated revenue of nearly $20.4 billion last year, according to an article ...
Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures are ...
AbbVie’s top job today centers on developing new sources of revenue out of the fear that biosimilars to its megablockbuster Humira will cause a precipitous sales decline starting in 2023. But after ...
Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...
AbbVie’s blockbuster drug Humira has more competition coming—the first FDA-approved biosimilar that may be substituted for the monoclonal antibody at the pharmacy. The competing Boehringer Ingelheim ...
No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results